Mirvetuximab soravtansine is currently being evaluated in the phase Ib/II FORWARD II study in combination with anticancer agents including Doxil (doxorubicin), Avastin (bevacizumab) and Paraplatin (carboplatin). The mirvetuximab
This is a follow-on investment from the foundation for achievement based on the development of a new pneumococcal vaccine which targets Streptococcus pneumoniae (pneumococcus) towards clinical testing. The
The drug can be taken in combination of sofosbuvir with or without ribavirin in genotypes 1 and 3. With this combination, three difficult to treat patient populations can
The PDAC recommendation is based on the efficacy results from FOCUS and CONNECT studies, which were specifically designed to evaluate the effect of Brintellix on certain aspects of
MRSA is a bacterium responsible for several difficult-to-treat infections in humans. It poses challenge in the healthcare sector due to high infection risk during treatment and surgery of
Emend, a substance P/neurokinin-1 receptor (NK1) antagonist, has already been approved for highly emetogenic chemotherapy. The approval of the new indication was based on data from a randomized,
The move follows the completion of a phase I study in healthy volunteers. FFP104, which was licensed from PanGenetics, is indicated to treat several autoimmune diseases and inflammatory
Cytori Therapeutics carried out the open-label, single-arm study in Denmark on 17 patients who had undergone radical prostatectomy within 5-18 months before the trial. A single intracavernous injection
The company claims that it is probably the first in the world to file for a global patent for Zika vaccine candidates which it calls Zikavac. The candidates
The completion has resulted in various development programs including those that target AMPK, eiF4E, Metnase, MTH1, PERK, and other indications. The company is working with partners to develop
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.